Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

NCT05024019 | Unknown Phase 2

• 1 other identifier: BPL-Nim-SCCHN-6
• Study Type: interventional
• Target: 95
• Locations: 1 country
• Sites: 6

Brief Summary

This study is a prospective, open label, multicenter, randomized controlled clinical trial. The main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent radiotherapy versus radiotherapy alone in high-risk patients with HNSCC not suitable for cisplatin after surgery. The subjects were randomly divided into study group (nimotuzumab combined with concurrent radiotherapy) and control group (radiotherapy alone) by 1∶1 stratified random method.

Conditions

Head and Neck Squamous Cell Carcinoma

Keywords

Nimotuzumab; HNSCC

Outcome Measures

Primary Outcomes (1)

• Disease free survival (DFS)

  2 year

Secondary Outcomes (5)

• Overall survival (OS)

  2 year

• Local area recurrence free survival (LRRFS)

  2 year

• Distant metastasis free survival (DMFS)

  2 year

• Quality of life assessed by EORTC QLQ-H&N35

  2 year

• Incidence of treatment-emergent adverse events

  2 year

Other Outcomes (1)

• The change of tumor related markers

  2 year

Study Arms (2)

Study group

EXPERIMENTAL

The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.

Drug: Nimotuzumab

Control group

NO INTERVENTION

The control group received radiotherapy alone.

Interventions

Nimotuzumab DRUG

The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.

Study group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years;
• Histology or imaging diagnosed as head and neck (oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer) squamous cell carcinoma; oropharyngeal cancer should be p16 negative (p16 positive defined as p16 ≥ 70%);
• The radical surgery has been completed and patients were suffered from any postoperative risk factors as follows: (1) extranodal extension (ENE); (2) pT3-4; pN2-3; (3) Nerve invasion (PNI) or vascular invasion (LVI); (4) Lymph node metastasis in zone IV or zone V (oral/oropharyngeal cancer); (5) Proximal margin (\< 5mm);
• Immunohistochemical detection indicated the EGFR expressions were positive;
• The patients were not suitable for cisplatin chemotherapy: (1) Age\>65 years; (2) ECOG PS score\>2; (3) Renal dysfunction (creatinine clearance \<60ml/min); (4) Severe tinnitus or hearing loss (need hearing aids or hearing tests show 25 decibels threshold or above at two consecutive frequencies); (5) peripheral neuropathy severer than 1 level ; (6) Unable to accept venous hydration, such as cardiac dysfunction or other comorbidities (judged by the investigator); (7) The patient refuses cisplatin chemotherapy;
• Imaging examination did not suggest distant metastasis;
• Expected survival time ≥ 6 months;
• The following criteria must be met (No transfusion of blood or blood products within 14 days prior to screening): Hb≥90g /L; ANC≥1.0×10\*9 /L; PLT≥80×10\*9 /L; white blood cell count ≥ 4×10\*9 /L; Biochemical examination need to meet the following criteria: serum total bilirubin (TBIL) ≤1.5 ULN; aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 ULN.
• For females of reproductive age, the patients must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and be willing to use a reliable method of contraception during the trial. Male subjects should use a reliable method of contraception from the beginning of treatment until 120 days after the last medication;
• The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up.

You may not qualify if:

• The patients received chemotherapies, PD-1 inhibitors, monoclonal antibody against EGFR, EGFR-TKI, anti-angiogenic drugs within 4 weeks before enrollment;
• The patients participated in other interventional clinical trials within 30 days before screening;
• There was a history of other malignant tumors within the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ;
• Poorly controlled concurrent diseases (such as heart failure, diabetes, hypertension, thyroid disease, mental illness, etc.);
• Known to be infected with HIV virus or active viral hepatitis or tuberculosis;
• There is major surgery within 30 days before taking the trial drug for the first time or there is planned surgery;
• Allergic to the drugs or their components used in this program;
• Pregnancy (confirmed by blood or urine HCG test) or breastfeeding women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment;
• Patients who are not suitable to participate in this research according to the evaluations of researchers;
• Those who are unwilling to participate in this study or unable to sign the informed consent form.

Sponsors & Collaborators

• Eye & ENT Hospital of Fudan University: lead

Study Sites (6)

The First Affiliated Hospital of Zhejiang University

Hangzhou, China

Location

Zhejiang Cancer Hospital

Hangzhou, China

Location

Jiangsu Province Hospital

Nanjing, China

Location

Ningbo Medical Center Lihuili Hospital

Ningbo, China

Location

Huadong Hospital Affiliated to Fudan University

Shanghai, China

Location

Shanghai General Hospital/First People's Hospital Affiliated with Shanghai Jiao Tong University

Shanghai, China

Location

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

nimotuzumab

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Central Study Contacts

Lei Tao

CONTACT

64377134; doctortaolei@163.com

Yang Guo

CONTACT

guoyangls@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 15, 2021
• First Posted: August 27, 2021
• Study Start: August 21, 2021
• Primary Completion: August 21, 2025
• Study Completion: August 21, 2025
• Last Updated: August 27, 2021

Record last verified: 2021-08

Locations

CN (6)